Российский кардиологический журнал (Oct 2005)

Lipoprotein (a) and apolipoprotein BD100 in coronary heart disease pathogenesis

  • K. I. Tebloev,
  • G. G. Arabidze,
  • O. V. Polyakova,
  • O. I. Afanasyeva,
  • M. I. Afanasyeva,
  • E. O. Skryabina

Journal volume & issue
Vol. 0, no. 5
pp. 20 – 23

Abstract

Read online

The aim of the study was to investigate lipid profile, lipoprotein(a) (Lp(a)), and apolipoprotein B-100 (apoB) levels in coronary heart disease (CHD) patients. In total, 575 patients aged 66,56±12,51 years (302 males aged 65,21±2,1 years and 273 females aged 67.57±10.85 years) with CHD diagnosis, verified by anamnesis, complaints, physical and instrumental examination, as well as 86 individuals aged 55,47±1,47 years (46 males aged 54,41±1,26 years and 40 females aged 56,53±12,04 years) without cardiovascular disease (control group), were examined. Apo(B) and Lp(a) (mg/dl) levels were substantially higher in CHD patients, and high-density Lp (HDL) levels - significantly lower in CHD patients, comparing to the control group. CHD patients demonstrated lipid profile inter-correlations: between cholesterol (CH) and Lp(a), CH and apoB, CH and triglycerides (TG), TG and apoB, low-density LP (LDL) and apoB, LDL and Lp(a). High predictive value of Lp(a) level over 27 mg/dl and apoB level over 128 mg/dl as CHD risk factors was demonstrated.

Keywords